Cardiff Oncology
CRDF
Cardiff Oncology (CRDF) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.17
- EPS estimate
- −$0.21
- EPS surprise
- +17.07%
- Revenue surprise
- −4.00%
- Revenue
- $120,000.00
- Revenue estimate
- $125,000.00
- Reported
- Nov 6, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 6, 2025 | −$0.21 | −$0.17 | +17.07% | $120,000.00 | SEC |
| Q2 2025 | Jul 29, 2025 | −$0.19 | −$0.21 | −9.09% | $121,000.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.19 | −$0.20 | −8.05% | $109,000.00 | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.25 | −$0.22 | +10.71% | $153,000.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.27 | −$0.25 | +7.24% | $165,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.25 | −$0.26 | −5.05% | $163,000.00 | SEC |
| Q1 2024 | May 2, 2024 | −$0.25 | −$0.22 | +11.47% | $205,000.00 | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.27 | −$0.21 | +21.38% | $156,000.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.28 | −$0.22 | +22.54% | $141,000.00 | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.26 | −$0.25 | +4.14% | $108,000.00 | SEC |
| Q1 2023 | May 4, 2023 | −$0.23 | −$0.25 | −10.62% | $83,000.00 | SEC |
| Q4 2022 | Mar 2, 2023 | −$0.24 | −$0.20 | +14.89% | $100,000.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.26 | −$0.20 | +24.24% | $93,000.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.25 | −$0.24 | +2.44% | $91,000.00 | SEC |
| Q1 2022 | May 5, 2022 | −$0.23 | −$0.25 | −7.16% | $74,000.00 | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.17 | −$0.23 | −33.95% | $133,000.00 | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.17 | −$0.17 | +0.00% | $86,000.00 | SEC |
| Q2 2021 | Aug 5, 2021 | −$0.15 | −$0.17 | −13.33% | $68,000.00 | SEC |
| Q1 2021 | May 6, 2021 | −$0.15 | −$0.14 | +5.08% | $72,000.00 | SEC |
| Q4 2020 | Feb 25, 2021 | −$0.14 | −$0.19 | −35.71% | $119,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Cardiff Oncology (CRDF) last report earnings?
Cardiff Oncology last reported on Nov 6, 2025, covering fiscal Q3 2025.
Did CRDF beat earnings estimates?
Yes. Cardiff Oncology reported EPS of −$0.17 for Q3 2025 against a −$0.21 estimate — a 17.07% beat.
How much revenue did CRDF report last quarter?
Cardiff Oncology reported $120,000.00 in revenue for Q3 2025, against a consensus estimate of $125,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.